{"contentid": 488237, "importid": NaN, "name": "UK\u00e2\u0080\u0099s NICE recommends Ondexxya", "introduction": "The UK\u00e2\u0080\u0099s National Institute for Care and Health Excellence (NICE) has recommended Ondexxya (recommend andexanet alfa) for reversing anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adult patients who experience a life-threatening or uncontrolled bleed in the gastrointestinal (GI) tract, US drugmaker Alexion Pharmaceuticals announced today.", "content": "<p>The UK&rsquo;s National Institute for Care and Health Excellence (NICE) has recommended Ondexxya (recommend andexanet alfa) for reversing anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adult patients who experience a life-threatening or uncontrolled bleed in the gastrointestinal (GI) tract, US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) announced today.</p>\n<p>Until now, there has been no licensed therapy to reverse FXa-associated major bleeds when treated with apixaban or rivaroxaban, Bayer&rsquo;s (BAYN: DE) Xarelto, which are increasingly used for the prevention and treatment of thrombotic events, such as deep vein thrombosis and pulmonary embolism, or if a patient is at high risk of a stroke due to an irregular heart rate (atrial fibrillation).</p>\n<p><strong>The company notes that:</strong></p>\n<ul>\n<li>Andexanet alfa is currently the first and only approved specific reversal agent of its kind;</li>\n<li>Studies show that andexanet alfa can reverse the anticoagulant effect of apixaban or rivaroxaban within two minutes of administration, and that 82% of patients responded well to the treatment; and</li>\n<li>Apixaban and rivaroxaban are used for the prevention and treatment of conditions such as deep vein thrombosis and pulmonary embolism, or if a patient is at high risk of a stroke due to an irregular heart rate (atrial fibrillation)</li>\n</ul>\n<p>Alexion acquired rights to andexanet last year along with its $1.4 billion buy of Portola Pharmaceuticals. Peak annual sales of the drug have been forecast at $600 million, on a conservative basis.</p>\n<p>The European Commission granted conditional Marketing Authorization for Ondexxya in Europe in April 2019. It was approved by the US Food and Drug Administration in May 2018, under the Andexxa name.</p>", "date": "2021-04-01 16:05:00", "meta_title": "UK\u00e2\u0080\u0099s NICE recommends Ondexxya", "meta_keywords": "Alexion Pharma, Ondexxya, Bleeding, GI, NICE, Recommendation", "meta_description": "UK\u00e2\u0080\u0099s NICE recommends Ondexxya", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 16:04:49", "updated": "2021-04-01 16:12:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/uk-s-nice-recommends-ondexxya", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "alexion-logo-big.jpg", "image2id": "alexion-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology", "topic_tag": "Focus On, Pricing, reimbursement and access, Regulation", "geography_tag": "UK, USA", "company_tag": "Alexion Pharmaceuticals, Portola Pharmaceuticals", "drug_tag": "AndexXa, Ondexxya", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 16:05:00"}